title: Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry.
abstract: OBJECTIVE
  Several immunoglobulin (IG) preparations have been approved for the immunomodulatory treatment of the neurological autoimmune diseases (AID) Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). Although efficacy has been proven in randomised clinical trials, long-term outcome data on drug utilization, effectiveness, tolerability, health related quality of life, and economic variables are lacking.
  
  
  METHODS
  In the prospective, observational internet-based SIGNS registry, patients of all age groups are eligible if they have received or are scheduled for IG therapy for neurological AID or primary or severe secondary immunodeficiency.
  
  
  RESULTS
  Of the 306 patients currently included in the database (1 November 2011), 51 have neurological AID (27 males; mean age 56 ± 15 years): 21 CIDP, 7 MMN, 11 multiple sclerosis (MS), 6 myasthenia gravis, 2 myositis, 4 others (no cases of GBS). Mean duration of disease since first symptoms was 7.8 years, and disease duration since diagnosis was 5.9 years. Eight different IG preparations have been reported as current therapy. According to SF-36, patients' quality of life is substantially impaired.
  
  
  CONCLUSIONS
  Present data indicate some off-label use of IG (e.g. in MS) in patients with neurological AID. Quality of life in these patients is substantially compromised. Increasing patient numbers and extended follow-up periods will provide data on treatment concepts and disease development in AID patients.
authors.affiliation: Department of Neurology, Hannover Medical School, Hannover, Germany. stangel.martin@mh-hannover.de
authors.forename: Martin
authors.initials: M
authors.lastname: Stangel
authors.forename: Ulrich
authors.initials: U
authors.lastname: Baumann
authors.forename: Michael
authors.initials: M
authors.lastname: Borte
authors.forename: Maria
authors.initials: M
authors.lastname: Fasshauer
authors.forename: Manfred
authors.initials: M
authors.lastname: Hensel
authors.forename: Dörte
authors.initials: D
authors.lastname: Huscher
authors.forename: Wilhelm
authors.initials: W
authors.lastname: Kirch
authors.forename: David
authors.initials: D
authors.lastname: Pittrow
authors.forename: Marcel
authors.initials: M
authors.lastname: Reiser
authors.forename: Ralf
authors.initials: R
authors.lastname: Gold
mesh_terms: D000328:Adult; D000368:Aged; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D056687:Off-Label Use; D011788:Quality of Life; D012042:Registries; D016896:Treatment Outcome
chemical_list: D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors